Quick Answer
REGENERON PHARMACEUTICALS, INC. reported Diluted EPS of $41.48 per share for fiscal year 2025.
REGENERON PHARMACEUTICALS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $41.48 | +8.2% |
| 2024 | $38.34 | +10.3% |
| 2023 | $34.77 | -9.0% |
| 2022 | $38.22 | -46.9% |
| 2021 | $71.97 | +135.8% |
| 2020 | $30.52 | +65.3% |
| 2019 | $18.46 | -13.3% |
| 2018 | $21.29 | +105.9% |
| 2017 | $10.34 | +34.3% |
| 2016 | $7.70 | +39.5% |
| 2015 | $5.52 | +85.2% |
| 2014 | $2.98 | -19.9% |
| 2013 | $3.72 | -44.9% |
| 2012 | $6.75 | +375.5% |
| 2011 | -$2.45 | -94.4% |
| 2010 | -$1.26 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $13.62 | +18.0% | +6.3% |
| June 30, 2025 | $12.81 | +3.2% | +76.2% |
| March 31, 2025 | $7.27 | +15.9% | -37.0% |
| September 30, 2024 | $11.54 | +29.8% | -7.0% |
| June 30, 2024 | $12.41 | +46.0% | +97.9% |
| March 31, 2024 | $6.27 | -12.6% | -29.5% |
| September 30, 2023 | $8.89 | -23.8% | +4.6% |
| June 30, 2023 | $8.50 | +13.8% | +18.5% |
- REGENERON PHARMACEUTICALS, INC. showed an increase of +8.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2010–2025 period, REGENERON PHARMACEUTICALS, INC.’s diluted eps has grown by 3392.1% (from $1.26 per share (loss) to $41.48 per share).
- The most recent figure is from REGENERON PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: